Cameron J. Koch
Department of Radiation Oncology
University of Pennsylvania School of Medicine
Philadelphia
PA 19104
USA
Name/email consistency: high
- Biodistribution and dosimetry of (18)F-EF5 in cancer patients with preliminary comparison of (18)F-EF5 uptake versus EF5 binding in human glioblastoma. Koch, C.J., Scheuermann, J.S., Divgi, C., Judy, K.D., Kachur, A.V., Freifelder, R., Reddin, J.S., Karp, J., Stubbs, J.B., Hahn, S.M., Driesbaugh, J., Smith, D., Prendergast, S., Evans, S.M. Eur. J. Nucl. Med. Mol. Imaging (2010)
- The radiation response of cells from 9L gliosarcoma tumours is correlated with [F18]-EF5 uptake. Koch, C.J., Shuman, A.L., Jenkins, W.T., Kachur, A.V., Karp, J.S., Freifelder, R., Dolbier, W.R., Evans, S.M. Int. J. Radiat. Biol. (2009)
- Importance of antibody concentration in the assessment of cellular hypoxia by flow cytometry: EF5 and pimonidazole. Koch, C.J. Radiat. Res. (2008)
- Oxygen sensor design: analysis and correction of problems associated with zero current, stability and structure. Koch, C.J. Adv. Exp. Med. Biol. (2003)
- Non-invasive PET and SPECT imaging of tissue hypoxia using isotopically labeled 2-nitroimidazoles. Koch, C.J., Evans, S.M. Adv. Exp. Med. Biol. (2003)
- Radiosensitization of hypoxic tumor cells by dodecafluoropentane: a gas-phase perfluorochemical emulsion. Koch, C.J., Oprysko, P.R., Shuman, A.L., Jenkins, W.T., Brandt, G., Evans, S.M. Cancer Res. (2002)
- Pharmacokinetics of EF5 [2-(2-nitro-1-H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide] in human patients: implications for hypoxia measurements in vivo by 2-nitroimidazoles. Koch, C.J., Hahn, S.M., Rockwell, K., Covey, J.M., McKenna, W.G., Evans, S.M. Cancer Chemother. Pharmacol. (2001)
- Co-localization of hypoxia and apoptosis in irradiated and untreated HCT116 human colon carcinoma xenografts. Koch, C.J., Chasan, J.E., Jenkins, W.T., Chan, C.Y., Laughlin, K.M., Evans, S.M. Adv. Exp. Med. Biol. (1998)
